These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36893893)

  • 1. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy.
    Moran B; Davern M; Reynolds JV; Donlon NE; Lysaght J
    Cancer Lett; 2023 Apr; 559():216121. PubMed ID: 36893893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylases and epigenetic therapies of hematological malignancies.
    Mercurio C; Minucci S; Pelicci PG
    Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
    Ali SR; Humphreys KJ; McKinnon RA; Michael MZ
    Drug Dev Res; 2015 Sep; 76(6):296-317. PubMed ID: 26303212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
    Miller CP; Singh MM; Rivera-Del Valle N; Manton CA; Chandra J
    J Biomed Biotechnol; 2011; 2011():514261. PubMed ID: 21765634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy of lymphoma using histone deacetylase inhibitors.
    Cotto M; Cabanillas F; Tirado M; García MV; Pacheco E
    Clin Transl Oncol; 2010 Jun; 12(6):401-9. PubMed ID: 20534395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC inhibitors as epigenetic regulators for cancer immunotherapy.
    Conte M; De Palma R; Altucci L
    Int J Biochem Cell Biol; 2018 May; 98():65-74. PubMed ID: 29535070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
    Mazzone R; Zwergel C; Mai A; Valente S
    Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
    Markozashvili D; Ribrag V; Vassetzky YS
    Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
    Zain J
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):671-704, ix. PubMed ID: 22520985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
    Sharma NL; Groselj B; Hamdy FC; Kiltie AE
    BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
    Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
    Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
    Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
    World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
    Terui Y
    Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
    Tiper IV; Webb TJ
    Cancer Immunol Immunother; 2016 Nov; 65(11):1411-1421. PubMed ID: 27614429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
    Shin HS; Choi J; Lee J; Lee SY
    Cancer Res Treat; 2022 Apr; 54(2):458-468. PubMed ID: 34517693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.